The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Vepdegestrant significantly improved progression-free survival in ESR1-mutant ER-positive, HER2-negative advanced breast cancer compared to Faslodex, with a median of 5.0 months versus 2.1 months. The ...

Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) led to a clinically meaningful and statistically significant improvement in overall survival (OS) vs ramucirumab (Cyramza) plus paclitaxel in the ...

The new drug application is supported by data from the phase 1/2 SOHO-01 trial. The US Food and Drug Administration has accepted for priority review the new drug application (NDA) for sevabertinib ...

The approval of Trastuzumab rezetecan was based on the pivotal HORIZON-Lung study led by Professor Lu Shun at Shanghai Chest Hospital, which demonstrated groundbreaking efficacy in HER2 ...

Sevabertinib shows promise for advanced NSCLC with HER2 mutations, achieving a 72.1% objective response rate in the SOHO-01 trial. Patients with HER2 YVMA insertions exhibited a 90% objective response ...

Regulatory submission is based on positive results from the ongoing Phase I/II SOHO-01 trial in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). Investigational agent ...